-
FDA advisory panel to consider OTC status of NSAIDs
SILVER SPRING, Md. — A pair of Food and Drug Administration advisory committees will be meeting Feb. 10 to talk about heart risks associated with use of NSAIDs and whether or not Bayer's Aleve (naproxen) carries a lower risk profile than other NSAIDs. The FDA is also considering potentially revoking OTC status of certain nonprescription NSAIDS, according to published reports.
-
CRN addresses study claiming children's vitamins generally exceed RDAs
NEW YORK — The Council for Responsible Nutrition on Monday helped to tone down the conclusions of a recent study reported by Reuters Health that found vitamin supplements marketed for infants and children contained more than the recommended amount of individual vitamins.